Suboxone vs. Subutex: Similarities & Differences

If you’re starting medication-assisted treatment for opioid use disorder, or you’re already on it and considering a change, this question comes up sometimes in Middle Tennessee: Suboxone, or Subutex? The names get used interchangeably in conversation, but the medications are not the same, and the choice between them belongs with your prescriber. This article walks through what the two medications share, where they differ, and what factors a clinician typically considers when recommending one. Treat it as preparation for a clinical conversation rather than medical advice.

Suboxone and Subutex both contain buprenorphine, a partial opioid agonist that treats opioid use disorder by easing cravings and withdrawal. The key difference is that Suboxone also contains naloxone (added to deter misuse by injection), while Subutex was the brand name for buprenorphine alone. According to the FDA, the Subutex brand was discontinued in the U.S. in 2011, although generic buprenorphine monoproduct remains available by prescription.

Key Takeaways

Both Suboxone and generic buprenorphine sublingual tablets (the medication previously sold as Subutex) contain buprenorphine, the medication that actually treats opioid use disorder.
Suboxone adds naloxone as a misuse deterrent; the buprenorphine monoproduct does not.
The brand name Subutex was discontinued in the U.S. in 2011; generic buprenorphine sublingual tablets remain available when clinically appropriate.
Pregnancy, history of misuse, formulation preference, and household safety can all factor into the choice.
The decision belongs with your prescriber; this article is preparation for that conversation.

What Suboxone and Subutex Have in Common

Both medications are forms of medication-assisted treatment (MAT), also known as Medications for Opioid Use Disorder (MOUD). Medication-assisted treatment is the evidence-based use of FDA-approved medications combined with counseling and behavioral therapies to treat substance use disorders. According to SAMHSA’s Treatment Improvement Protocol 63, buprenorphine-based MAT reduces opioid cravings and withdrawal, lowers overdose risk, and improves long-term outcomes for people with opioid use disorder.

The active ingredient in both Suboxone and Subutex is buprenorphine. Buprenorphine is a partial opioid agonist, which means it activates the same brain receptors as full opioids like heroin or oxycodone, but only partially. The American Society of Addiction Medicine describes this partial activation as the reason buprenorphine eases withdrawal without producing the same intensity of euphoria, and why it has a ceiling effect that lowers overdose risk compared with full agonists.

Both medications are taken sublingually (under the tongue) and absorbed through the lining of the mouth. Both are prescribed by clinicians trained to treat opioid use disorder.

How Suboxone and Subutex Differ

The differences come down to formulation and the presence of a second ingredient, naloxone.

The Naloxone Component

Suboxone is a combination of buprenorphine and naloxone. Naloxone is an opioid antagonist (the same medication used to reverse overdose in the form of Narcan). In Suboxone, naloxone serves as a misuse deterrent. Taken correctly under the tongue, naloxone is poorly absorbed and has minimal effect. Injected, it triggers precipitated withdrawal. Precipitated withdrawal is the abrupt onset of intense withdrawal symptoms that happens when an opioid antagonist or partial agonist displaces other opioids from the brain’s receptors. That deterrent is the central design rationale for the combination product, according to the FDA label for Suboxone.

The buprenorphine monoproduct (historically sold as Subutex) contains buprenorphine without naloxone. The active medication is the same as in Suboxone; the combination simply omits the naloxone component.

Formulation Differences

Suboxone is commonly prescribed as a sublingual film, although tablet versions and other branded combinations like Zubsolv and Bunavail exist. The buprenorphine monoproduct is typically a sublingual tablet. Films and tablets dissolve under the tongue and require staying still while they absorb, usually for several minutes.

Some people find one format easier to tolerate based on taste, dissolve time, or how the medication fits a daily routine. Those preferences are worth bringing up with a prescriber.

Brand Availability Today

According to the FDA, Reckitt Benckiser Pharmaceuticals voluntarily discontinued the Subutex brand in the United States in 2011. The FDA confirmed that the withdrawal was not due to safety or effectiveness concerns; the manufacturer chose to focus on combination products with built-in misuse deterrents. Generic buprenorphine sublingual tablets remain available and are still prescribed when clinically appropriate. Many people in recovery, and even some clinicians, still use “Subutex” as shorthand for the monoproduct, which is part of why the brand name persists in conversation.

When a Prescriber May Recommend Buprenorphine Alone (Generic Subutex)

Pregnancy is the most well-known factor. The American College of Obstetricians and Gynecologists has historically recommended the buprenorphine monoproduct during pregnancy to avoid any prenatal exposure to naloxone. ACOG’s guidance also notes that more recent studies of the combination product have not found adverse outcomes compared with the monoproduct, and the conversation has evolved in many obstetric settings. The decision in pregnancy depends on the prescriber’s clinical judgment, current evidence, and the individual’s history.

Other situations where a prescriber may consider the monoproduct include documented sensitivity or allergic reaction to naloxone (uncommon, but real), specific medical contexts that warrant avoiding combination products, and clinical preference based on the person’s response to one formulation over the other.

When a Prescriber May Recommend Suboxone

For general opioid use disorder treatment outside of pregnancy, a buprenorphine-naloxone combination is often the default option. The American Society of Addiction Medicine’s National Practice Guideline for the Treatment of Opioid Use Disorder treats combination products as a standard first-line choice because of the added misuse deterrent.

The combination product is also commonly recommended when there’s a history of injection misuse of opioids, when household safety is a concern (other family members, especially young children, who might encounter the medication), or when the prescriber and individual together prefer the additional layer of misuse protection. Formulation preference between film and tablet also plays a role.

Questions to Ask Your Doctor

Walking into a clinical appointment with a list helps. These are practical questions worth bringing to a buprenorphine conversation:

Which medication are you recommending for me, and why?
How does the medication you’re recommending fit my specific situation, including pregnancy plans, other prescriptions, and mental health needs?
What dose are we starting at, and how will we adjust it?
What does induction (the first day or two of starting buprenorphine) look like, and how do I avoid precipitated withdrawal?
What side effects should I watch for, and what should I report right away?
How long do you expect I’ll be on this medication?
How will we coordinate the medication with counseling and any other treatment I’m doing?
What’s the protocol if I miss a dose or run out?

Common Concerns About Buprenorphine-Based MAT

“Am I Just Trading One Addiction for Another?”

This question lives at the top of almost every MAT conversation, and it deserves a straight answer. Research from the National Institute on Drug Abuse shows that medication-assisted treatment reduces opioid use, lowers overdose mortality, and improves treatment retention compared with non-medication approaches. Buprenorphine stabilizes brain chemistry so people can engage in counseling, rebuild work and family life, and address the root drivers of opioid use.

Carrying stigma about MAT is common. Many people who walk through the doors at JourneyPure have spent years hearing that “real” recovery means white-knuckling it without medication. The evidence base for MAT is strong, and the framing of medication as a moral compromise has been gradually replaced in clinical practice by the recognition that it saves lives.

How Long Will I Need to Take It?

There is no fixed answer to this question. SAMHSA’s TIP 63 emphasizes that the duration of buprenorphine treatment is individualized: some people benefit from a year of MAT, others from several years, and others from long-term or indefinite treatment. The right length supports each person’s recovery and gets revisited with the prescriber over time.

Side Effects to Discuss With Your Prescriber

Common side effects of buprenorphine can include constipation, headache, nausea, insomnia, sweating, and dental issues with long-term sublingual use. The FDA has issued warnings about dental complications from buprenorphine sublingual products and recommends ongoing dental care during treatment. Any new or worsening symptom is worth a call to the prescriber.

MAT Works Best Alongside Therapy and Community

Medication alone treats the neurobiology of opioid use disorder. The reasons people started using, the relationships that frayed, the trauma underneath, the daily routines that don’t fit a life in recovery: those need a different kind of work. SAMHSA’s TIP 63 makes the case that buprenorphine is most effective as part of a comprehensive treatment approach that includes counseling, peer support, and treatment for co-occurring mental health conditions.

For many people, that combination works best inside a structured treatment program where medication, therapy, and community show up together rather than as separate appointments scattered across the week.

JourneyPure At The River: Medication-Assisted Treatment in Tennessee

JourneyPure At The River is a 127-acre addiction treatment campus nestled along the West Fork Stones River in Murfreesboro, serving Middle Tennessee, Greater Nashville, Davidson County, and Williamson County. The continuum runs from medical detox through residential treatment to intensive outpatient, with dual diagnosis treatment built into every level of care for the trauma, depression, and anxiety that so often travel alongside opioid use.

One thing that sets JourneyPure apart is the staff. Many people on the clinical and support teams are in recovery themselves and bring that lived experience into the work. The voice in the room is camaraderie first, clinical authority second. As the team puts it, we’ve been there.

Experiential therapy and adventure therapy (kayaking on the river, equine sessions, ropes courses) function as clinical interventions. The river and trails are part of the treatment plan. JourneyPure is in-network with BCBS, Humana, and TRICARE, and the admissions team can verify benefits before you commit to anything. If you’re not currently connected to a treatment team and want to learn what comprehensive MAT at JourneyPure looks like, a conversation is a reasonable first step. Call (629) 222-9449.

Frequently Asked Questions

What’s the Main Difference Between Suboxone and Subutex?

The main difference is naloxone. Suboxone contains buprenorphine and naloxone, while Subutex was the brand name for buprenorphine alone. Naloxone is included in Suboxone as a deterrent against misuse by injection. Both medications treat opioid use disorder through the buprenorphine component.

Is Subutex Still Available?

The brand name Subutex was discontinued in the United States in 2011 according to the FDA. Generic buprenorphine sublingual tablets (the same active medication that was sold under the Subutex brand) remain available by prescription when clinically appropriate.

Is Subutex Safer Than Suboxone During Pregnancy?

The buprenorphine monoproduct has historically been recommended during pregnancy to avoid prenatal naloxone exposure. According to the American College of Obstetricians and Gynecologists, more recent studies of buprenorphine-naloxone in pregnancy have not found adverse outcomes. The choice is one to discuss with your obstetrician and addiction prescriber based on your specific situation.

Can I Switch From Suboxone to Subutex or Vice Versa?

Switching between buprenorphine formulations is possible and is sometimes done for clinical reasons. The switch should happen under a prescriber’s direction. Dosing equivalence and timing matter, and a self-managed switch can lead to inadequate dosing or unintended withdrawal.

How Long Do People Stay on Buprenorphine?

The duration of buprenorphine treatment is individualized. SAMHSA’s TIP 63 notes that some people benefit from a year of MAT, others from several years, and others from indefinite treatment. The right length is the one that supports each person’s recovery and is revisited with the prescriber over time.

Will Buprenorphine Show Up on a Drug Test?

Buprenorphine does not appear on a standard opioid panel; a specific buprenorphine test is required to detect it. If drug testing is part of your work or legal situation, telling your prescriber so the prescription can be documented is worth doing in advance.

Does Insurance Cover Suboxone or Subutex in Tennessee?

Most major insurance plans cover buprenorphine medications and the clinical services that accompany them under the Mental Health Parity and Addiction Equity Act. JourneyPure At The River is in-network with BCBS, Humana, and TRICARE, and the admissions team can verify benefits at no cost by calling (629) 222-9449.

Speak With a Recovery Specialist

You’re not alone in this, and you won’t be alone here. Recovery is hard, and thoughtful preparation for a medication conversation is part of doing it well. Whether you’re in Murfreesboro, Nashville, or anywhere across Middle Tennessee, a recovery specialist at JourneyPure can answer questions about MAT, walk you through what comprehensive opioid treatment in Tennessee looks like, verify your insurance, and help you understand what a next step might look like. Call (629) 222-9449.

Crisis and Emergency Resources

If you or someone you know is in a substance use or mental health crisis, help is available now. Contact the SAMHSA National Helpline at 1-800-662-HELP (4357) for free, confidential treatment referrals 24/7. Reach the 988 Suicide and Crisis Lifeline by calling or texting 988. The Crisis Text Line is available by texting HOME to 741741. For emergencies, call 911.

Learn More

Will Long